Concepts (171)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma | 10 | 2021 | 73 | 2.400 |
Why?
|
| Bone Neoplasms | 12 | 2020 | 111 | 2.390 |
Why?
|
| Soft Tissue Neoplasms | 8 | 2021 | 39 | 2.130 |
Why?
|
| Brachytherapy | 2 | 2018 | 24 | 1.010 |
Why?
|
| Orthopedics | 2 | 2019 | 90 | 0.740 |
Why?
|
| Spine | 1 | 2019 | 41 | 0.660 |
Why?
|
| Spinal Neoplasms | 1 | 2019 | 22 | 0.660 |
Why?
|
| Incidental Findings | 1 | 2019 | 25 | 0.650 |
Why?
|
| Joint Instability | 2 | 2019 | 76 | 0.650 |
Why?
|
| Diffusion of Innovation | 1 | 2018 | 34 | 0.620 |
Why?
|
| Interdisciplinary Communication | 1 | 2018 | 58 | 0.610 |
Why?
|
| Internship and Residency | 2 | 2019 | 313 | 0.600 |
Why?
|
| Radiation Dosage | 1 | 2018 | 84 | 0.600 |
Why?
|
| Humerus | 2 | 2013 | 32 | 0.590 |
Why?
|
| Chondrosarcoma | 4 | 2020 | 7 | 0.570 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 128 | 0.560 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2021 | 367 | 0.550 |
Why?
|
| Lipoma | 1 | 2015 | 7 | 0.510 |
Why?
|
| Tendon Injuries | 1 | 2014 | 38 | 0.470 |
Why?
|
| Humans | 31 | 2021 | 32005 | 0.450 |
Why?
|
| Osteochondroma | 1 | 2013 | 2 | 0.440 |
Why?
|
| Giant Cell Tumors | 1 | 2013 | 4 | 0.440 |
Why?
|
| Limb Salvage | 7 | 2021 | 22 | 0.440 |
Why?
|
| Tendons | 1 | 2013 | 59 | 0.430 |
Why?
|
| Wrist Joint | 1 | 2013 | 60 | 0.420 |
Why?
|
| Magnetic Resonance Imaging | 11 | 2020 | 1328 | 0.420 |
Why?
|
| Cell Proliferation | 2 | 2020 | 604 | 0.400 |
Why?
|
| Antimicrobial Cationic Peptides | 2 | 2020 | 14 | 0.360 |
Why?
|
| Retrospective Studies | 12 | 2021 | 3509 | 0.360 |
Why?
|
| Middle Aged | 17 | 2020 | 11817 | 0.350 |
Why?
|
| Radiography | 4 | 2016 | 376 | 0.350 |
Why?
|
| Neoplastic Stem Cells | 2 | 2020 | 99 | 0.340 |
Why?
|
| Adult | 15 | 2020 | 9345 | 0.320 |
Why?
|
| Femoral Neoplasms | 2 | 2010 | 4 | 0.270 |
Why?
|
| Female | 18 | 2020 | 19959 | 0.260 |
Why?
|
| Male | 15 | 2018 | 19165 | 0.260 |
Why?
|
| Aged | 13 | 2018 | 10301 | 0.260 |
Why?
|
| Neoplasm, Residual | 4 | 2016 | 25 | 0.260 |
Why?
|
| Predictive Value of Tests | 3 | 2018 | 876 | 0.250 |
Why?
|
| Physical Examination | 3 | 2013 | 92 | 0.250 |
Why?
|
| Fibrous Dysplasia of Bone | 2 | 2014 | 2 | 0.240 |
Why?
|
| Treatment Outcome | 7 | 2018 | 3306 | 0.240 |
Why?
|
| Biopsy | 3 | 2013 | 259 | 0.240 |
Why?
|
| Young Adult | 8 | 2020 | 2636 | 0.220 |
Why?
|
| Biopsy, Needle | 2 | 2016 | 93 | 0.210 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2018 | 78 | 0.210 |
Why?
|
| Fractures, Spontaneous | 2 | 2019 | 16 | 0.210 |
Why?
|
| Aged, 80 and over | 8 | 2016 | 3990 | 0.210 |
Why?
|
| Adolescent | 8 | 2016 | 3539 | 0.210 |
Why?
|
| Amyloidosis | 1 | 2021 | 14 | 0.200 |
Why?
|
| Orthopedic Procedures | 2 | 2019 | 89 | 0.190 |
Why?
|
| Joint Diseases | 1 | 2021 | 37 | 0.190 |
Why?
|
| Tibia | 2 | 2014 | 56 | 0.190 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2010 | 5 | 0.190 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2020 | 8 | 0.180 |
Why?
|
| Bone Transplantation | 2 | 2016 | 45 | 0.170 |
Why?
|
| Office Visits | 1 | 2010 | 73 | 0.170 |
Why?
|
| Subcutaneous Fat | 1 | 2020 | 47 | 0.170 |
Why?
|
| Mycetoma | 1 | 2009 | 1 | 0.170 |
Why?
|
| Leg Dermatoses | 1 | 2009 | 2 | 0.170 |
Why?
|
| Ambulatory Care | 1 | 2010 | 108 | 0.170 |
Why?
|
| Foot Diseases | 1 | 2009 | 10 | 0.170 |
Why?
|
| Ulcer | 1 | 2009 | 3 | 0.170 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2009 | 15 | 0.160 |
Why?
|
| Lower Extremity | 1 | 2020 | 100 | 0.160 |
Why?
|
| Knee Injuries | 1 | 2019 | 42 | 0.160 |
Why?
|
| Palliative Care | 1 | 2019 | 52 | 0.160 |
Why?
|
| Neurosurgical Procedures | 1 | 2019 | 99 | 0.160 |
Why?
|
| Combined Modality Therapy | 3 | 2016 | 560 | 0.160 |
Why?
|
| Patient Care Team | 1 | 2019 | 129 | 0.150 |
Why?
|
| Specialties, Surgical | 1 | 2018 | 28 | 0.150 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2018 | 13 | 0.150 |
Why?
|
| Athletic Injuries | 1 | 2019 | 82 | 0.150 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2009 | 154 | 0.150 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2019 | 89 | 0.150 |
Why?
|
| Surgical Wound Infection | 1 | 2018 | 84 | 0.150 |
Why?
|
| Range of Motion, Articular | 2 | 2013 | 187 | 0.140 |
Why?
|
| Tarsal Bones | 1 | 2016 | 5 | 0.140 |
Why?
|
| Wound Healing | 1 | 2018 | 185 | 0.140 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2016 | 8 | 0.140 |
Why?
|
| Pediatrics | 1 | 2018 | 155 | 0.140 |
Why?
|
| Pain | 1 | 2009 | 288 | 0.140 |
Why?
|
| Arthrodesis | 1 | 2016 | 20 | 0.140 |
Why?
|
| Shoulder Joint | 1 | 2008 | 126 | 0.140 |
Why?
|
| Prognosis | 5 | 2015 | 1497 | 0.130 |
Why?
|
| Diagnosis, Differential | 4 | 2014 | 517 | 0.130 |
Why?
|
| Postoperative Complications | 2 | 2020 | 780 | 0.130 |
Why?
|
| Risk Assessment | 2 | 2018 | 1426 | 0.120 |
Why?
|
| Time Factors | 2 | 2018 | 2149 | 0.120 |
Why?
|
| Granuloma, Foreign-Body | 1 | 2014 | 7 | 0.120 |
Why?
|
| Osteitis Deformans | 1 | 2014 | 2 | 0.120 |
Why?
|
| Enchondromatosis | 1 | 2014 | 3 | 0.120 |
Why?
|
| Exostoses, Multiple Hereditary | 1 | 2014 | 2 | 0.120 |
Why?
|
| Sutures | 1 | 2014 | 20 | 0.120 |
Why?
|
| Risk Factors | 2 | 2018 | 3876 | 0.110 |
Why?
|
| Extremities | 3 | 2021 | 50 | 0.110 |
Why?
|
| United States | 2 | 2019 | 3939 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 458 | 0.110 |
Why?
|
| Wound Infection | 1 | 2012 | 10 | 0.100 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2012 | 34 | 0.100 |
Why?
|
| Recovery of Function | 1 | 2013 | 199 | 0.100 |
Why?
|
| Child | 4 | 2010 | 2438 | 0.090 |
Why?
|
| Cell Survival | 2 | 2020 | 284 | 0.080 |
Why?
|
| Neoplasm Staging | 3 | 2016 | 447 | 0.080 |
Why?
|
| Artificial Limbs | 1 | 2008 | 1 | 0.080 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2008 | 50 | 0.080 |
Why?
|
| Cell Line, Tumor | 2 | 2020 | 726 | 0.080 |
Why?
|
| Reoperation | 2 | 2013 | 226 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 2265 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2016 | 190 | 0.060 |
Why?
|
| Femur | 2 | 2014 | 74 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 317 | 0.050 |
Why?
|
| beta 2-Microglobulin | 1 | 2021 | 6 | 0.050 |
Why?
|
| Amyloid | 1 | 2021 | 15 | 0.050 |
Why?
|
| Curettage | 1 | 2010 | 9 | 0.050 |
Why?
|
| Antigens, Surface | 1 | 2020 | 24 | 0.050 |
Why?
|
| STAT3 Transcription Factor | 1 | 2020 | 25 | 0.050 |
Why?
|
| Retinal Dehydrogenase | 1 | 2020 | 2 | 0.050 |
Why?
|
| Florida | 1 | 2010 | 37 | 0.050 |
Why?
|
| Spheroids, Cellular | 1 | 2020 | 37 | 0.050 |
Why?
|
| Necrosis | 1 | 2010 | 53 | 0.050 |
Why?
|
| Chromatin | 1 | 2020 | 25 | 0.040 |
Why?
|
| Itraconazole | 1 | 2009 | 6 | 0.040 |
Why?
|
| Toes | 1 | 2009 | 15 | 0.040 |
Why?
|
| Periosteum | 1 | 2009 | 9 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 104 | 0.040 |
Why?
|
| Osteosarcoma | 1 | 2009 | 11 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 918 | 0.040 |
Why?
|
| Hemangioma | 1 | 2009 | 19 | 0.040 |
Why?
|
| Arthrography | 1 | 2009 | 11 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2009 | 40 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 2021 | 282 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 261 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 633 | 0.040 |
Why?
|
| Fluoroscopy | 1 | 2008 | 40 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2019 | 127 | 0.040 |
Why?
|
| Prosthesis Failure | 1 | 2008 | 45 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2008 | 151 | 0.040 |
Why?
|
| Prostheses and Implants | 1 | 2008 | 42 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 762 | 0.040 |
Why?
|
| Knee Joint | 1 | 2009 | 142 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2008 | 483 | 0.040 |
Why?
|
| Pain Measurement | 1 | 2009 | 350 | 0.040 |
Why?
|
| Fracture Fixation, Internal | 1 | 2008 | 116 | 0.040 |
Why?
|
| Comorbidity | 1 | 2009 | 566 | 0.040 |
Why?
|
| Ifosfamide | 1 | 2016 | 6 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2008 | 684 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2016 | 101 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2016 | 21 | 0.030 |
Why?
|
| Cisplatin | 1 | 2016 | 76 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2019 | 333 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2008 | 753 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2016 | 67 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2016 | 82 | 0.030 |
Why?
|
| Pregnancy | 1 | 2009 | 997 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2016 | 163 | 0.030 |
Why?
|
| Skin Transplantation | 1 | 2015 | 49 | 0.030 |
Why?
|
| Ilium | 1 | 2014 | 15 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 538 | 0.030 |
Why?
|
| Surgical Flaps | 1 | 2015 | 72 | 0.030 |
Why?
|
| Pelvic Bones | 1 | 2014 | 32 | 0.030 |
Why?
|
| Survival Rate | 1 | 2016 | 877 | 0.030 |
Why?
|
| Ribs | 1 | 2014 | 44 | 0.030 |
Why?
|
| Calcinosis | 1 | 2014 | 146 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2013 | 58 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 412 | 0.020 |
Why?
|
| Hip Prosthesis | 1 | 2008 | 14 | 0.020 |
Why?
|
| Prosthesis Implantation | 1 | 2008 | 40 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2008 | 220 | 0.020 |
Why?
|
| Walking | 1 | 2008 | 209 | 0.020 |
Why?
|
| Age Factors | 1 | 2008 | 1188 | 0.020 |
Why?
|